



# DOCTOR DISCUSSION GUIDE

## Intermediate-Risk Non-Muscle Invasive Bladder Cancer (NMIBC)

### STUDY DETAILS:

PIVOT-006 is a Phase 3 randomized study evaluating an investigational drug called cretostimogene grenadenorepvec for adults with Intermediate-Risk NMIBC. All patients will receive surgical treatment on study as part of Standard-of-Care. 50% of patients will receive cretostimogene in addition to surgical treatment. For patients who do not receive cretostimogene, you will be offered cretostimogene if your bladder cancer recurs. In the treatment arm, patients will receive TURBT plus cretostimogene.

Cretostimogene is an experimental drug and not all risks are known. It is being studied to determine whether it is effective and safe in the treatment of NMIBC.

Cretostimogene will be given intravesically in the bladder using a thin tube called a catheter. Throughout the study, doctors will monitor your health and how your cancer is responding to the treatment.

### QUESTIONS TO HELP GUIDE CONVERSATIONS WITH YOUR HEALTHCARE PROFESSIONAL:

- Do I meet the requirements to join this study?
- What will my responsibilities be if I participate?
- What are the possible benefits and risks of participating in this clinical trial?
- Who will oversee my medical care?
- What support/resources does the study team offer to participants and caregivers?
- Can I stop participating in the study after it has begun?

If you would like to learn more about the eligibility requirements of this study, please contact us at:

[Recruitment@cgoncology.com](mailto:Recruitment@cgoncology.com)

